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Abstract: Type 2 diabetes mellitus (T2DM), a disease on the rise and with huge economic burden
to health care systems around the globe, results from defects in insulin action (termed insulin
resistance) combined with impaired insulin secretion. Current methods of prevention and treatments
for insulin resistance and T2DM are lacking in number and efficacy and, therefore, there is
a need for new preventative measures and targeted therapies. In recent years, chemicals found
in plants/herbs have attracted attention for their use as functional foods or nutraceuticals for
preventing and treating insulin resistance and T2DM. Rosemary is an evergreen shrub indigenous
to the Mediterranean region and South America, which contains various polyphenols. Rosemary
extract and its polyphenolic constituents have been reported to have antioxidant, anti-inflammatory,
anticancer, and anti-hyperglycemic properties. The current review summarizes the existing in vitro
and in vivo studies examining the anti-diabetic effects of rosemary extract and its polyphenolic
components and highlights the known mechanism of action.
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a disease resulting from impairments in insulin action
and insulin secretion [1]. Diminished insulin action and insulin secretion lead to deregulation of
glucose and fat metabolism in various tissues including skeletal muscle, adipose tissue and liver and
failure to maintain normal blood glucose levels. This prolonged pathological state characterized
by hyperglycemia and hyperlipidemia leads to complications such as retinopathy; neuropathy;
nephropathy; and microvascular, macrovascular and cardiovascular problems. According to the
World Health Organization and the International Diabetes Federation (IDF) estimates, T2DM is rapidly
growing and will be affecting more than 439 million adults by 2030 [2]. At present, there is no cure for
diabetes mellitus as is true for many of the major chronic diseases inflicting the world’s population at
large. Current therapeutic strategies for diabetes mellitus are aimed at management and alleviation of
the underlying pathological processes and include lifestyle modifications such as healthy diet, weight
management and regular physical activity coupled with medication/drug interventions [3].
Oral medications for T2DM treatment include drugs that stimulate insulin release from β-cells
(sulfonylureas and meglitinides); inhibit intestinal glucose absorption (α-glucosidase-inhibitors);
increase peripheral glucose transport; and reduce hepatic glucose output through inhibition of
gluconeogenesis (biguanides and thiazolidinediones) (Figure 1). Metformin (biguanide) is the most
widely used treatment for T2DM; unfortunately, it is associated with increased lactic acid acidosis [4]
and 30% of patients report gastrointestinal problems such as diarrhea, cramps, nausea and vomiting
that can lead to discontinuation of the drug [5]. In the last decade, several new drugs for T2DM were
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introduced. Dipeptidyl peptide 4 (DDP-4) inhibitors or gliptins (sitagliptin, saxagliptin, and linagliptin)
inhibit glucagon release resulting in reduced blood glucose levels, however significant side effects
include increased risk of heart failure, pancreatitis and pancreatic cancer [6]. Moreover, glucagon-like
peptide 1 (GLP-1) receptor agonists (lxenatide and liraglutide) stimulate insulin and inhibit glucagon
release thereby lowering the blood glucose levels. Although GLP-1 agonists have lower risk of
hypoglycemia compared to sulfonylureas and meglitinides, they work in the same pathway as
DPP-4 inhibitors and there are concerns of an increased risk of pancreatitis and pancreatic cancer [7].
Oral sodium-glucose cotransporter 2 (SGLT2) inhibitors (canagliflozin and dapagliflozin) are the
newest anti-diabetic drugs, and work by endorsing urinary glucose excretion and inhibiting renal
glucose reabsorption. Although they show promising results for T2DM therapy, their side-effects may
include severe urinary tract infections, ketoacidosis and hypotension [8,9].
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other hand, despite the availability of various compounds to manage T2DM, the disease is a global 
health problem with 50% of the affected individuals living in poverty stricken areas in Africa and 
Asia and therefore there is an urgent need to find effective but less expensive medicine. The study of 
novel compounds that can exert an insulin-like effect, increase insulin sensitivity and even improve 
efficacy of existing medication at lower doses and reduce their adverse effects is highly desired and 
they will widen the spectrum of preventative and treatment options for insulin resistance and T2DM. 
The use of plants for healing purposes predates recording history and forms the origin of much 
of modern medicine [10]. Phytotherapy is still the mainstay of about 75–80% of the world’s 
population centralized in developing countries for primary health care. Notably, in the last few years, 
there has been a major rise in phytotherapy in the developed world. In Germany and France, many 
herbs and herbal extracts are used as prescription drugs and their sales in the countries of the 
European Union were around 6 billion in 1991 and might be over 20 billion dollars now [10,11]. 
Many conventional drugs originate from plant sources including aspirin (from willow tree bark), 
digoxin (from foxglove), quinine (from cinchona bark), and morphine (from the opium poppy). Prior 
to and after the discovery of insulin, herbs with hypoglycemic effects have been used in folk medicine 
and are still prevalent. As evidence of this concept, metformin, which is the first line of treatment for 
T2DM, was purified from the French lilac Galega officinalis L. 
The development of drugs from plants continues, with drug companies engaged in large-scale 
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The development of drugs from plants continues, with drug companies engaged in large-scale
pharmacologic screening of various plants including herbs. Any part of a plant, including leaves, stems,
flowers, roots, and seeds can be formulated as raw material or extracts. Maceration of plants with water,
alcohol or other solvents results in extraction of their active pharmaceutical ingredients including fatty
acids, sterols, alkaloids, polyphenols, glycosides, saponins, and others [10]. Recently, a web server
(http://bio-hpc.eu/dia-db) has been established that can be used to predict diabetes-related bioactive
compounds. The prediction is accomplished by: (1) inverse virtual screening of the input molecule
chosen by the user against a set of protein targets identified as key elements in diabetes; and (2) by
comparing it to the database of anti-diabetic drugs. This website could be utilized in plant extracts to
explore the anti-diabetic potential of specific phytochemical contents of the extract.
2. Phenolic Compounds of Rosemary
Rosemary (Rosmarinus officinalis L.) is an aromatic, evergreen shrub plant belonging to the labiatae
family (Lamiaceae) and indigenous to the Mediterranean region and South America [12–16]. The fresh
and dried leaves have been extensively used as seasoning as well as in traditional medicine [16].
Historically, rosemary has been used medicinally to treat renal colic and dysmenorrhea, stimulate hair
growth and relieve symptoms caused by respiratory disorders [12,14,17]. Today, rosemary extract is
often used in aromatherapy to treat anxiety-related conditions and increase alertness [15,17].
Formulations of rosemary include the raw leaves, and extracts of rosemary. Conventional
extraction methods such as hydrodistillation, decoction and maceration along with other methods
including pressurized liquid extract, enzyme-assisted extraction, nanofiltration and solid-phase
extraction have been employed to extract polyphenols from plant materials [10,18].
Rosemary extract (RE) contains different classes of polyphenols including phenolic acids,
flavonoids and phenolic terpenes [18–22] (Table 1). Phenolic acids include: (a) the hydroxycinnamic
acids: rosmarinic acid, chlorogenic acid, p-coumaric acid, m-hydroxybenzoic acid, coumaroylquinic
acid, ferulic acid and coumaric acid; (b) the hydroxybenzoic acids: vanillic acid, syringic acid, caffeic
acid, protocatechuic acid, dicaffeoylquinic; acid and (c) the hydroxyphenylacetic acids: homovanillic
acid and p-hydroxybenzoic acid. Flavonoids include the flavones: apigenin, luteolin, hispidulin and
genkwanin. In addition, they include the flavonols: rutin, kaempferol, kaempferol-3-O-rutinoside,
naringenin-C-hexoside, hesperetin, apigenin-7-O-glucoside, quercetin, isorhamnetin-3-O-hexoside,
apigenin-acetylglucosidase, isohamnetin-lutelion, and isorhamnetin-luteolin [18,21,22]. Phenolic
terpenes found in rosemary include diterpenes such as carnosol, carnosic acid, rosmanol, epirosmanol,
isorosmanol, rosemaridiphenol, rosmadial, Methoxycarnosol and Methoxycarnosate [18,21,22].
In addition, triterprnres such as betulinic acid, oleanolic acid, and ursolic acid (Table 1) [23,24].
The polyphenols found in highest quantity in RE are carnosic acid (CA), carnosol (COH) and
rosmarinic acid (RA) (Figure 2) [22,25] and their production is influenced by growth conditions such
as sunlight exposure, soil quality, and water availability [10]. Furthermore, anatomical regions of
this herbal plant have varying levels of total phenolic content whereby the leaves contain the highest
concentration of polyphenols in comparison to stem, branch and flower regions [26]. On the other
hand, the choice of solvent and extraction method affects the chemical composition of the extract
with the possibility of losing lipid soluble chemicals by an aqueous-based extraction method and
water soluble chemicals by nonpolar solvent (ethanol, methanol)-based extraction. Regardless of the
extraction method used, RE has been shown to have antioxidant, anti-inflammatory, anti-microbial,
anti-tumorigenic, and anti-hyperglycemic properties. These biological effects are highly correlated
with the polyphenolic content and CA, COH and RA are suggested to be responsible. The present
review focuses on the existing studies examining the anti-diabetic effects of RE. Studies examining the
anti-diabetic properties of CA, COH and RA are also included. In the following sections, in vitro and
in vivo animal and human studies are presented.
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Table 1. Polyphenolic profile of Rosemary extract (RE).
Polyphenols
Phenolic Acids Flavonoids Phenolic Terpenes
Hydroxycinnamic
Acids
Hydroxybenzoic
Acids
Hydroxyphenylacetic
Acids Flavones Flavonols Diterpenes Triterprnres
Rosmarinic acid
(C18H16O8) [18]
Vanillic acid
(C8H18O4) [22]
Homovanillic acid
(C9H10O4) [22]
Apigenin
(C27H30O15) [18]
Rutin (C27H30O16) [18]
Carnosol (C20H26O4)
[18,21,22]
Betulinic acid
(C30H48O3) [23,24]
Chlorogenic acid
(C16H18O9) [18,21,22]
Syringic acid
(C9H10O5) [18,21,22]
p-Hydroxybenzoic
acid (C7H6O3) [22]
Luteolin (C15H10O6)
[18]
Kaempferol (C15H10O6)
[18,21,22]
Carnosic acid
(C20H28O4) [18,21,22]
Oleanolic acid
(C30H48O3) [23,24]
o-,m-,p-Coumaric
acid (C9H8O3)
[18,21,22]
Caffeic acid (C9H7O4)
[18,21,22]
Hispidulin
(C16H12O6) [23,24]
Kaempferol-3-O-rutinoside
(C27H30O15) [18,21,22]
Rosmanol (C20H26O5)
[18,21,22]
Ursolic acid
(C30H48O3) [23,24]
m-Hydroxybenzoic
acid (C7H6O3)
[18,21,22]
Protocatechuic acid
(C7H6O4) [18,21,22]
Genkwanin
(C16H12O5) [23,24]
Naringenin-C-hexoside
(C21H22O10) [21,22]
Epirosmanol (C20H26O5)
[21,22]
Coumaroylqunic acid
(C16H18O8) [21,22]
Dicaffeoylquinic acid
(C25H24O12)
[18,21,22]
Hesperetin (C28H34O15)
[18]
Isorosmanol (C20H26O5)
[18,21,22]
Ferulic acid
(C16H20O9) [21,22]
Apigenin-7-O-glucoside
(C21H20O10) [18]
Rosmaridiphenol
(C20H28O3) [18]
Quercetin (C15H10O7) [18]
Rosmadial (C20H24O5)
[18]
Isorhamnetin-3-O-hexoside
(C22H22O12) [23,24]
Methoxycarnosol [23,24]
Apigenin-acetylglucosidase
[23,24]
Methoxycarnosate
[23,24]
Isohamnetin-lutelion [23,24]
Isorhamnetin-luteolin
[23,24]
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3. Evidence of Anti-Diabetic Effects of Rosemary Extract: In Vitro Studies (Cell Free Models)
Digestive enzymes convert starch to maltose and iso-maltose which then travel to the small
intestine where they are converted along with sucrose to monosaccharides (glucose and fructose) by
α-glucosidase (sucrase and maltase) and transported by the intestinal sodium-glucose cotransporter
thereby increasing blood glucose levels [27]. Inhibitors of α-glucosidase are used in the management
of hyperglycemia present in T2DM. Acarbose is a currently prescribed anti-diabetic drug that
reduces the rate of glucose absorption through inhibition of α-glucosidase in the brush border
of the small intestine and pancreatic α-amylase found in the lumen of the small intestine [27].
RE exposure (5.5 mg/mL–55 mg/mL) was found to have significant α-glucosidase inhibitory activity
(60% decrease) [28], while, in another study, the IC50 was found to be 683–711 µg/mL, making RE
extract the most potent among 31 other extracts of herbs and spices tested [29] (Table 2). Furthermore,
RA (8.88 mM) was also demonstrated to significantly inhibit porcine pancreatic amylase activity [30].
RE was found to be a potent inhibitor of DPP-IV (IC50 of 6.5 ± 0.4 µM gallic acid equivalents
(GAE)) comparable to sitagliptin (0.05 ± 0.01 µM) [31]. Computational modeling experiments
demonstrated that carnosol found in highest levels in RE had a strong binding affinity to DPP-IV [31].
The breakdown of triglycerides is regulated by lipases such as hormone-sensitive lipase (HSL)
in adipose tissue and pancreatic lipase (PL) in the lumen of the small intestines. Excessive activation
of hormone sensitive lipase leads to increased serum levels of free fatty acids (FFA) and insulin
inhibits this hormone [32]. RE at concentrations of 6.3–200 µg/mL had a dose-dependent inhibitory
activity ranging from 2.4–64.9% for HSL and 36.8–95.1% for PL effects that were less potent but in
the same direction as orlistat, an FDA approved anti-obesity drug [33]. Pure RA was also shown to
inhibit HSL and PL in a dose dependent manner although the degree of inhibition was lower than
the whole extract [33]. Additionally, in vitro analysis indicated that CA enriched rosemary extract
(100 µg/mL) inhibited PL activity by 70% [34]. COH, a major RE constituent, was found to have
potent inhibitory activity (IC50 = 62.5 µM) against rat liver diacylglycerol acyltransferase 1 (DGAT1),
an enzyme that plays a fundamental role in triglyceride synthesis [35]. COH (20 µM, 40 µM) was
found to inhibit intracellular de novo triglyceride synthesis by 67.5–90.6% without affecting cell
viability [35]. These studies clearly indicate that similar to the action of insulin, rosemary, CA and RA
have antilipolytic activity in vitro.
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Table 2. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: cell-free
model studies.
Cell-Free Model Dose Effects Reference
α-glycosidase RE 5.5–55 mg/mL ↓ α-glycosidase activity (60%) [28]
α-glycosidase 50% ethanolic RE(IC50: 83–711 µg/mL)
↓ α-glucosidase [29]
Porcine Pancreatic α-amylase (PPAM) RA 8.88 mM ↓ PPAM activity (85%) [30]
Dipeptidyl Peptidase IV (DPP-IV); Protein
Tyrosine Phosphatase 1B (PTP1B)
Methanolic RE
(IC50 = 6.5 ± 0.4 µM)
RA (IC50 = 14.1 ± 1.7 µM)
COH (IC50 > 100 µM)
↓ DPP-IV activity (50%)
RE (↓ PTP1B 40.9 ± 7.2%). [31]
Porcine pancreatic lipase (PL); Hormone
sensitive lipase (HSL)
Methanolic RE 6.3–200 µg/mL
RE (IC50 = 13.8 for PL and
95.2 µg/mL for HSL)
RA (IC50 = 125.2 for PL and
51.5 µg/mL for HSL)
↓ PL and HSL activity
RE (↓ PL: 36.8–95.1%)
RE (↓ HSL: 2.4–64.9%)
RE > RA
[33]
Human PL Acetone RE 100 µg/mL rich in CA ↓ human PL (70%) [34]
Rat liver diacylglycerol acyltransferase
(DGAT1) COH (IC50 = 62.5 ± 2.1 µM)
↓ DGAT1 activity
(67.5–90.6%) [35]
4. Evidence of Anti-Diabetic Effects of Rosemary Extract: In Vitro Studies (Hepatocytes)
In vitro studies have shown that RE (100 µg/mL) has an insulin-like effect to inhibit the
production of glucose by hepatocytes. RE was shown to significantly suppress gluconeogenesis
in HepG2 hepatocytes (Table 3) [36]. In another study, RE (2.0–50 µg/mL) was shown to significantly
increase hepatocyte (HepG2) glucose consumption in a dose-dependent manner (6% to 21%) [37].
In addition, a significant decrease in cellular glycogen content and increase glycolytic rate was
seen [37]. CA (10–20 mM), a major polyphenolic constituent of RE, prevented palmitate-induced
lipid accumulation in hepatocytes [38] indicating that CA may potentially block cellular lipid
accumulation in the long term and help against insulin resistance and T2DM. Furthermore, it was
found that treatment of HepG2 hepatocytes with COH (20–40 µM) resulted in inhibition of
intracellular triglyceride synthesis via an effect that was associated with significant inhibition of
diacylglycerol acyltransferase (DGAT1), the enzyme that plays a pivotal role in catalyzing the
formation of triglycerides from Acetyl-CoA and diacylglycerol [35]. It is important to note that
inhibition of DAGT1 has been proposed as a target approach for T2DM and obesity treatment.
RE’s polyphenolic constituents may also provide protection against chemically-induced reactive
oxygen species production and hepatocyte death. RA exhibited significant cytoprotective effects
against mycotoxin-induced reactive oxygen species (ROS) production and induction of apoptosis by
blocking effects on caspase-3 activation in hepatocytes [39].
Table 3. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: in vitro
studies (hepatocytes).
Cell/Model Treatment Effects Reference
HepG2 hepatocytes Methanolic RE100 µg/mL ↓ gluconeogenesis [36]
HepG2 hepatocytes Methanolic RE 0.4, 2, 10,
50 µg/mL
↑ glucose consumption
[37]
↑ glycolytic rate
↓ glycogenesis comparable to metformin
↑ β-oxidation
↓ decreased fatty acid synthesis
↔ cell viability
HepG2 hepatocytes CA 10–20 µM
↓ palmitate-induced lipid accumulation
[36]↔ cell viability
HepG2 hepatocytes COH 20–40 µM
↓ de novo formation of intracellular TG
[35]↔ cell viability
HepG2 hepatocytes RA 25–50 µM
↓ apoptosis
[39]↓ ROS production
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5. Evidence of Anti-Diabetic Effects of Rosemary Extract: In Vitro Studies (Adipocytes)
Treatment of 3T3-L1 adipocytes with CA (3 µM) and COH (3 µM) inhibited the differentiation
of 3T3-L1 pre-adipocytes into mature adipocytes and increased intracellular glutathione (GSH),
an important antioxidant that prevents against ROS-induced damage (Table 4) [40]. Similarly,
rosemary extract and CA were demonstrated to inhibit 3T3-L1 adipocyte differentiation, in part
through inhibition of the transcription factor PPARγ [41] (Table 4). An increase in glucose uptake and
intracellular lipid levels was seen in 3T3-L1 adipocytes treated with RE (50 µg/mL) (Table 4) [42].
Table 4. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: in vitro
studies (adipocytes).
Cell Treatment Effects Reference
3T3-L1 adipocytes CA 3 µM, COH 3 µM
↓ differentiation
[40]↑ intracellular GSH
3T3-L1 adipocytes Acetone RE 10–30 µg/mLCA 0.3–20 µM
Inhibited adipocyte differentiation
↔ cell viability [41]
3T3-L1 adipocytes RE 50 µg/mL ↑ intracellular lipid [42]↑ glucose uptake
3T3-L1 adipocytes CA 0.1–10 µM
↓ intracellular lipid accumulation
[43]
↓ TG content (15.5–39.8%)
↓ GPDH activity
↔ cell viability
3T3-L1 adipocytes
pretreated with LPS CA 0–20 µM
↓mRNA expression of TNFα, IL-6 and MCP-1
[44]
↓ TLR4 protein expression
↓ Phospho-ERK levels
↓ NF-κB activation
In contrast, treatment with CA (0.1–10 µM) resulted in reduced intracellular lipid accumulation
(19.1–33.4%), TG content (15.5–39.8%) and glycerol-3-phosphate dehydrogenase (GPDH) activity
in 3T3-L1 adipocytes [43]. The activity of cytosolic GPDH, a key regulatory enzyme involved in
triglyceride synthesis, dose-dependently decreased in CA treated adipocytes [43].
Corroborating with the above findings, CA significantly decreased mRNA expression of
PPARγ, C/EBPα and SREBP1 indicating that it affects PPARγ/SREBP1 medicated adipogenesis [43].
Interestingly, CA treated adipocytes had a lower monounsaturated fatty acid (MUFA) to saturated
fatty acid (SFA) ratio compared to control cells which was associated with a reduction of both mRNA
and protein expression levels of stearoyl-CoA desaturase 1 (SCD1), a PPARγ dependent enzyme
responsible for conversion of SFA to MUFA. MUFAs function as the major substrates for the synthesis
of triglycerides and cellular membrane phospholipids in adipocytes, and an increased ratio of MUFA:
SFA is correlated with de novo lipogenesis (Table 4) [43].
Carnosic acid treatment (1–20 uM) prevented LPS-stimulated elevations in the mRNA expression
of tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and monocyte chemoattractant protein-1
(MCP-1) indicating a significant reduction in the inflammatory response of adipocytes [44].
Together, these findings suggest effects of RE and RE polyphenols on adipocyte lipid accumulation
and anti-inflammatory effects.
6. Evidence of Anti-Diabetic Effects of Rosemary Extract: In Vitro Studies (Skeletal Muscle Cells)
Skeletal muscle tissue is important target of insulin and accounts for approximately 80% of insulin
mediated glucose uptake in the postprandial state. As a consequence, it plays a predominant role
in glucose homeostasis. Treatment of L6 myotubes with RE increased glucose uptake in a dose and
time dependent manner [45]. Maximum stimulation seen with 5 µg/mL of RE was comparable to
maximum stimulation seen with insulin (100 nM) and metformin (2 mM) (Table 5) [45].
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Table 5. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: in vitro
studies (muscle cells).
Cell/Model Treatment Effects Reference
L6 myotubes Methanolic RE0.1–50 µg/mL
↑ glucose uptake (GU) dose-
and time-dependent
Max stimulation: 5 µg/mL for 4 h
comparable to insulin and metformin.
↔ cell viability
[45]
L6 myotubes CA 1–50 µM
↑ GU in a dose- and time-dependent manner
Max stimulation: 20 µM for 6 h comparable to
insulin and metformin
↔ cell viability
[46]
L6 myotubes Methanolic CA0.1–10 µM
↑ GU dose- and time-dependent
Max stimulation: 2 µM for 4 h comparable
to insulin and metformin
↔ cell viability
[47]
In addition, treatment of L6 myotubes with CA (20 µg/mL for 6 h) resulted in significant increase
in glucose uptake [46]. Furthermore, in another study by Naimi et al., 2016, CA significantly increased
the glucose uptake in a dose- and time-dependent manner with concentration as low as 2 µM CA [47].
As proof-of-concept, the studies suggest that RE and its components increase skeletal muscle glucose
uptake (rate-limiting step in skeletal muscle glucose metabolism) although other potential effects
downstream of glucose uptake in this tissue remain to be explored.
All of the above in vitro studies indicate that RE has the potential to affect key insulin target
tissues (liver, fat, and muscle) and directly induce anti-diabetic effects.
7. Evidence of Anti-Diabetic Effects of Rosemary Extract: In Vivo Animal Studies
Anti-hyperglycemic effects of rosemary and its components have been evaluated in different
animal models of T2DM. Experimental interventions such as chemical (streptozotocin and alloxan)
and dietary (high fat and high fructose diets) modifications have been employed to induce T2DM
in animal models to study the effects of rosemary on associated biomarkers. Due to the lack of
standardized pharmacological and clinical evidence, the formulations and doses of rosemary and its
components used in these animal studies are variable. Notably, rosemary has not been extensively
evaluated in clinical trials involving humans. Collectively, the current in vivo models demonstrate
that rosemary and its main components CA and RA possess significant in vivo anti-hyperglycemic
and anti-hyperlipidemic properties as outlined below.
8. Streptozotocin (STZ)-Induced Diabetes Model
Streptozotocin (STZ) is traditionally used to induce both type 1 and type 2 diabetes mellitus by
promoting β-cell death through alkylation of DNA [48]. While a high dose of STZ potently impairs
insulin secretion mimicking type 1 diabetes, low doses are known to induce a mild impairment of
insulin secretion resembling the clinical features of T2DM. The reported studies reciprocally utilize
low dose STZ to study the acute and chronic effects of rosemary and its polyphenolic constituents.
In streptozotocin (STZ)-induced diabetic mice, administration of an aqueous RE (10 g/L) for three
months resulted in significant decrease in fasting plasma glucose (FPG) level (Table 6) [49]. There were
no changes in alkaline phosphatase activity, bilirubin, and creatine indicating that rosemary did not
cause cytotoxicity and histotoxicity [49]. In another study, administration of 50% ethanol extract of
rosemary (20 mg/kg/day) in STZ rats significantly decreased plasma glucose levels due to inhibition of
intestinal glucosidase enzyme activity [29]. In a more recent study, daily administration of aqueous RE
(200 mg/kg/day) for three weeks caused significant reductions in blood glucose levels of both normal
and STZ-induced diabetic rats [50]. These effects were associated with increased serum catalase (CAT),
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superoxide dismutase (SOD), glutathione peroxidase (GPx), vitamin C and vitamin G, while decreased
lipid peroxidation marker MDA levels [50]. Similar effects were seen on blood glucose levels in
STZ-induced diabetic rats given aqueous RE (1.11 g/mL) for four weeks [51]. In addition, the extract
significantly reduced plasmatic FPG, TG, TC and low density lipoprotein (LDL) while increasing
high density lipoprotein (HDL) and erythrocytes levels [51]. In agreement with the above studies,
the fasting plasma blood glucose levels as well as TC, LDL and TG levels were significantly reduced
while HDL was increased in STZ-induced diabetic rats given aqueous RE (200 mg/kg/day) two weeks
before and three weeks after STZ injection [52]. Administration of aqueous RE (200 mg/kg/day)
for 21 days in STZ-induced diabetic rats resulted in decrease in FPG, TC and total antioxidant
capacity [53]. Furthermore, administration of aqueous RE (200 mg/kg/day) for four weeks prior
and to streptozotocin injection in rats significantly protected against STZ-induced elevations in blood
glucose levels which was correlated with a significant protection against pancreatic β-cell loss [54]
In addition, RE increased serum insulin, C-peptide while decreased alanine aminotransferase (ALT)
and aspartate aminotransferase (AST). Administration of dried rosemary leaves (5 g/100 g of diet)
for approximately six weeks in STZ-induced diabetic and healthy Sprague-Dawley rats decreased
the FPG, glycated hemoglobin (HbA1c), TC and TG and LDL levels in STZ- induced rats without
effecting the plasma glucose levels or the lipid profile in the control group [55]. Oral administration of
RE (200 mg/kg/day) with or without moderate intensity exercise training for eight weeks resulted in
reduction of FPG and increased serum insulin levels in STZ-induced diabetic rats [56]. These effects
were associated with an increased antioxidant activity including increase in serum CAT, SOD and
GPx while decreasing malondialdehyde (MDA) [56]. In agreement, a more recent study showed
that RA (120–200 mg/kg) dose-dependently decreased plasma glucose levels, and improved insulin
sensitivity as supported by HOMA-IR analysis [57]. In STZ and high fat diet (HFD) induced diabetic
rats, RA (577 µg/mL) decreased FPG levels and increased insulin levels without affecting liver
glycogen levels [58]. These effects were associated with inhibition of intestinal brush border membrane
levels of SGLT1 by 50%, an active glucose transporter responsible for glucose absorption into the
bloodstream [58]. Oral administration of RE (200 mg/kg/day) for six weeks protected against the
reduced antioxidant status of diabetic rats with decreased GSH, CAT, and SOD; and increased lipid
peroxidation marker MDA levels [59]. Assessment of renal biomarkers including serum creatinine,
uric acid and urea levels showed that RE had renoprotective effects (Table 6) [59].
9. Alloxan-Induced Diabetes Model
In addition to the STZ-induced diabetic model, the alloxan-induced diabetes animal model
is also used extensively. Alloxan causes diabetes by rapid depletion of pancreatic β-cells leading
to inflammation and sustained hyperglycemia secondary to a reduction in insulin release into
circulation. In alloxan-induced diabetic rabbits, ethanol RE (200 mg/kg) for one week led to
a significant reduction in FPG and increase in insulin levels (Table 6) [60]. In contrast, another
study indicated that intramuscular administration of volatile oil of RE (25 mg/kg) for 30, 60 and
120 min inhibited insulin release and increased blood glucose levels leading to hyperglycemia in
normal and alloxan-induced diabetic rabbits [61]. In another study, oral administration of powdered
RE added as 20% of diet or 20% aqueous RE for 45 days to alloxan-induced diabetic rats significantly
decreased the FPG levels compared to control [62]. In addition, the treatment demonstrated
to reduce alloxan-induced hepatocyte vacuolar degeneration, necrosis, small hemorrhages and
dilatation of hepatic sinusoids indicating hepatoprotective effects [62]. Moreover, administration
of RA (100–200 mg/kg) to alloxan-induced diabetic rats for eight weeks significantly inhibited
glomerular hypertrophy, glomerular number loss and glomerulosclerosis compared with diabetic
control indicating RA’s renoprotective properties [63]. Administration of 250 and 500 mg/kg/day of
RE mixed with water (70%) for 63 days in male rats did not affect serum blood glucose, TG, TC levels
or body weight but testosterone levels, spermatogenesis, sperm density and motility were significantly
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decreased [64]. In addition, alanine aminotransferase (ALT) and aspartate aminotransferase (AST),
enzymes released due to liver damage, were also decreased (Table 6).
10. Genetically-Induced Diabetes Models
Oral administration of CA (approximately 17 mg/kg/day) to obese leptin receptor deficient
mice for five weeks resulted in significant protection against fat-induced fasting and non-fasting
hyperglycemia, improved glucose tolerance as well as decreased serum insulin levels [65]. In addition,
CA significantly inhibited weight gain, decreased regional areas of visceral fat, and prevented against
fat accumulation in white adipose tissue and liver [65]. Moreover, animals supplemented with CA
exhibited decreased serum levels of TG, TC, and ALT, as well as significantly decreased hepatic lipid
storage [65]. In contrast, obese mice and their lean counterparts fed 0.5% ethanol extract of rosemary
enriched with CA (40%) incorporated in their standard chow for 64 days did not show significant
differences in their glucose levels compared to control rats, although circulating insulin levels were
found to be significantly decreased only in the lean rats (Table 6) [66]. Noteworthy, the plasma glucose
levels in all animals were within normal physiological range with a non-significant, slight increase in
obese counterparts. The study also demonstrated a significant inhibition of gastric lipase (GL) in the
stomach and pancreatic lipase (PL) in small intestine of rats consuming the RE [66].
11. Diet-Induced Diabetes Model
Apart from animal models of genetic and chemically-induced obesity and T2DM, the effects of RE
have been examined in dietary animal models of obesity and T2DM. Daily, dietary supplementation of
RE (500 mg/kg) standardized to contain 20% CA for 16 weeks in mice that were started on a high-fat
diet (HFD) as juveniles significantly protected against HFD-induced elevations in plasma glucose
and TC levels compared with HFD control mice (Table 6) [34]. Notably, fasting insulinemia remained
low during the length of the study and no significant differences were observed between the groups.
Correlating with the observed reductions in total cholesterol levels, HFD mice supplemented with
RE displayed significant decreases in fat mass and one to twofold increase in total fecal lipid content
compared to HFD-fed control mice [34]. Additionally, another study indicated that administration
CA (20 mg/kg) in 5–20 mg/kg olive oil loaded mice, significantly repressed the elevation of TG
levels, prevented epididymal fat gain and inhibited pancreatic lipase activity [67]. Administration
of 200 mg/kg of RE for 50 days in mice fed high fat diet, resulted in reduced body weight (b.w) and
fat mass and increase of fecal lipid excretion, while hepatic triglyceride content was decreased [68].
Similarly, daily administration of aqueous RE (100 mg/kg b.w) to high-cholesterol fed mice for
36 days resulted in significant decline in plasma TG, TC, LDL levels, while HDL levels were increased
compared to control mice [69]. Furthermore, administration of aqueous RE (70–140 mg/kg b.w) and
non-esterified phenolic RE (7–14 mg/kg b.w) for four weeks resulted in significant reduction in TC and
non-HDL levels compared to control [70]. High-fructose fed mice given daily dose of RA (100 mg/kg
b.w) for 60 days decreased fasting plasma glucose levels, improved glucose tolerance and reduced
plasma insulin and glycated HbA1c levels (Table 6) [71].
Nutrients 2017, 9, 968 11 of 19
Table 6. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: in vivo
animal studies.
Animal Model Dose Glucose Other Measures Reference
Streptozotocin (STZ)-Induced Diabetic Model
STZ-induced diabetic Swiss
albino mice
Ad libitum (10 g leaves of
rosemary in 1 L boiling
water) for 3 months
↓ FPG in healthy and
diabetic animals
↔ creatinine, urea
bilirubin, total albumin,
alkaline phosphatase
[49]
STZ-induced diabetic male aqueous and ethanolic RE
20 mg/kg/day
↓ plasma glucose ↓ α-glucosidase (AGc) [29]ddY mice
Male Wistar rats RA 577 µg/mL as drinkingfluid for 14 days
↓ FPG
↓ OGTT
↓ HOMA-IR indices
↑ serum insulin
↓ hepatic glycogen
content [58]
STZ-induced diabetic male
albino rats
aqueous RE,
200 mg/kg/day for 3 weeks ↓ FPG ↑ vitamin C [50]
STZ-induced diabetic male
albino rats
aqueous RE 4 g/kg/day for
4 weeks ↓ FPG (20%)
↓ TC, TG, LDL
↑ HDL [51]
STZ-induced diabetic male
albino rats
aqueous RE,
200 mg/kg/day 2 weeks
prior and 3 weeks after STZ
↓ FPG (36.9%) ↓ TC, TG, LDL ↑HDL↑ hemoglobin [52]
STZ-induced diabetic male
albino rats
aqueous RE, 200
mg/kg/day for 21 days ↓ FPG
↓ TC
↓ TG
↑ TAC
[53]
STZ-induced diabetic male
albino rats
aqueous RE,
200 mg/kg/day 2 weeks
prior and 3 weeks after STZ
↓ FPG in both groups
↑ serum insulin
↑ C-peptide
↓ β-cell loss
↑ total albumin [54]
STZ-induced diabetic male
Dawley rats
Dried rosemary leaves
powder 5 g/100 g of diet
↓ FPG (53.97%)
↓ HbA1c (24.56%)
↓ TG (45.43%)
↓ TC (39.31%)
↓ LDL (33.89%)
[55]
Male albino Wistar rats
aqueous RE 200 mg/kg/day
with/without moderate
intensity exercise training
for 8 weeks
↓ FPG
↑ Serum CAT, SOD, GPx
↑ serum insulin
↓MDA
[56]
Sprague-Dawley male
albino rats
aqueous RE 200 mg/kg/day
for 6 weeks ↓ FPG
↑ Serum CAT, SOD, GSH
↓MDA
↓ urea, uric acid and
creatinine levels
[59]
Male Wistar rats
Intraperitoneal injection of
120, 160, 200 mg/kg RA for
7 days (acute) and 28 days
(chronic)
↓ FPG
↓ OGTT
↓ HOMA-IR indices
↑ ITT
Normalized serum
insulin
↓ hepatic PEPCK
expression/gluconeogenesis [57]
Alloxan-Induced Diabetes Model
Alloxan-induced diabetic
rabbits
ethanol RE, 200 mg/kg for
6 h (acute); for 1 week
(subacute)
↓ FPG in healthy and
diabetic rabbits
↑ plasma insulin
↓MDA
↑ SOD
↑ CAT
[60]
Alloxan-induced male
diabetic rabbits
volatile RE, 25 mg/kg
intramuscular injection for
30, 60 and 120 min
↑ serum glucose
[61]
↓ serum insulin
Alloxan-induced
Sprague-Dawley male
albino rats
20% aqueous RE and 20%
RE powdered food for
45 days
↓ FPG
↓ hepatocyte necrosis
↓ small hemorrhages
↓ hepatocyte degradation
[62]
Alloxan-induced
Sprague-Dawley
uninephrectomized rats
RA 100–200 mg/kg/day for
8 weeks
↓ glomerulosclerosis
↓ creatinine and urea
↓ glomerular number
↓ serum MDA
[63]
Male adult Sprague-Dawley
rats
70% aqueous RE, 250 and
500 mg/kg/day for 63 days ↔ serum glucose
↔ body weight TG, TC
↓ alanine
aminotransferase (ALT)
↓ Aspartate
Aminotransferase (AST)
↓ spermatogenesis
↓ testosterone
↓ sperm motility
[64]
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Table 6. Cont.
Animal Model Dose Glucose Other Measures Reference
Genetically-Induced Diabetes Models
Male ob/ob mice CA 17 mg/kg/day for5 weeks
↓ FPG (18%)
↓ OGTT glucose
↓ serum insulin (47%)
↓ TC (24%)
↓ TG (60%)
↓ plasma FFA (13%)
↓ hepatic lipids
↓ ALT (64%)
[65]
Female Zucker lean (fa/+)
and obese (fa/fa) rats
0.5% w/w of aqueous RE
enriched with CA for
64 days
↔ plasma glucose
↓ insulin levels in lean
animals
Inhibited gastric lipase
activity in both lean (70%)
and obese animals (80%)
↓ Serum total cholesterol,
TG, LDL
↑ HDL
[66]
Diet-Induced Diabetes Models
HFD-treated male C57BL/6J
mice
aqueous RE,
containing 20% CA
500 mg/kg/day for
16 weeks
↓ FPG (72%)
↔ insulin
↓ body weight
↑ fecal total lipid content
(1–2 fold)
↓ fat mass
↓ TC (68%)
↔ TG
[34]
HFD- (olive oil) treated male
ddY mice
CA 20 mg/kg for 14 days
COH 200 mg/kg for 14 days
↓ body weight (7%)
↑ epididymal fat
↓ pancreatic lipase (IC50
12 and 4.4 µg/mL for CA
and COH respecively)
[67]
HFD-treated male C57BL/6J
mice
ethanolic RE 20 or
200 mg/kg/day for 50 days
↔ FPG
↔ glucose tolerance
↔ insulin
↓ body weight and fat
mass (64% and 57%)
↓ Hepatic TG (39%)
↔ serum TG and TC
↑ fecal lipid excretion
[68]
Diet-induced HC female
BALB/c mice
aqueous RE,
100 mg/kg/day for 36 days
↓ TC, TG, LDL
↑ HD [69]
Diet-induced HC Wistar rats
aqueous RE, aqueous
70–140 mg/kg/day
RE non-esterified phenolic
7–14 mg/kg/day of for
4 weeks
↓ TC (39.8%)
↓ non-HDL (44.4%) [70]
Fructose-fed Swiss albino
mice
RA 100 mg/kg/day for
60 days
↓ FPG levels
↓ HbA1c
↓ OGTT glucose
↓ plasma insulin
↑ diaphragm glucose
utilization [71]
In addition to T2DM, type 1 diabetes mellitus (T1DM), an autoimmune disorder, is characterized
by pancreatic β-cell destruction and hyperglycemia. Very limited number of studies investigating
the effects of RE and its polyphenols in T1DM exist. A study demonstrated that co-treatment of
RA and anti-CD154 monoclonal antibody improved islet allograft survival in a murine model [72].
In addition, the co-treatment resulted in fewer apoptotic cells and increased expression of insulin
and glucagon [72]. Pancreatic islet transplantation is an area of intense research in the field
of T1DM and immunosuppressants are used to reduce transplant rejection, however, they have
detrimental/debilitating side effects. This study indicated that RE polyphenols improved outcome
and minimized side effects when used in islet transplantation, however, further research is required to
investigate their effectiveness in T1DM.
12. Anti-Diabetic Effects of Rosemary Extract and Its Main Polyphenolic Constituents: In Vivo
Human Studies
In addition to numerous in vitro and in vivo studies, RE has been recently investigated in humans.
Participants were randomly selected into three groups and treated with 2, 5 or 10 g/day of dried
rosemary leaf powder for eight weeks [73] (Table 7). Blood samples were taken from participants
before and after the study. FPG was decreased by 18.25%, 15.74% and 11.2% in the 10, 5 and 2 g/day
group, respectively. TC levels were significantly decreased by 34.48% in the 10 g/day group and
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17.97% and 11.48% in the 5 g/day and 2 g/day groups, respectively. LDL cholesterol in this group
was also significantly lowered by 32.28% in the 10 g/day treated group, and 28.46% and 15.58%
in the 5 g/day and 2 g/day groups, respectively. Additionally, HDL cholesterol was increased by
22.91% in the 10 g/day group and 15.21% and 4.54% in the 5 g/day and 2 g/day groups, respectively.
Furthermore, triglyceride levels were also decreased by 29.06% in the 10 g/day group and 21.3%
and 14.97% in the 5 g/day and 2 g/day groups, respectively. In addition to the improvement in the
overall lipid profile, rosemary powder seems to exhibit high antioxidant properties by decreasing
MDA by 36.21%, 12.43% and 13.6% in the 10 g/day, 5 g/day and 2 g/day treated groups, respectively.
Glutathione reductase (GR) was decreased by 15.36%, 6.73%, and 0.95% in the 10 g/day, 5 g/day
and 2 g/day treated groups respectively. Vitamin C indicated an increase by 19.93%, 11.37% and
8% in the 10 g/day, 5 g/day and 2 g/day treated groups, respectively. In addition, β carotene
levels increased by 45.23%, 33.33% and 7.5% in the 10 g/day, 5 g/day and 2 g/day treated group.
Additionally, there have been a few studies indirectly examining the effects of rosemary supplements
with non-conclusive results. An observational, prospective, monocenter study examined the effect of
21 days of oral supplementation of aqueous RE (containing 77.7 mg RE with 0.97 mg COH, 8.60 mg
CA, and 10.30 mg RA) in twelve healthy young volunteers found a significant decrease in plasminogen
activator-inhibitor-1 (PAI-1) levels suggesting that RE may have anti-inflammatory and anti-blood
clotting activity in vivo [74]. Another observational study demonstrated that administration of RE
and oleanolic acid (440 mg thrice a day for four weeks and additional 880 mg twice a day for four
weeks) in patients with osteoarthritis, fibromyalgia, and rheumatoid arthritis was protective against
inflammatory rheumatic diseases, particularly in those with initial serum c-reactive protein (CRP)
levels >7.0 mg/L (Table 7) [75].
Table 7. Anti-diabetic Effects of Rosemary Extract and its Main Polyphenolic Constituents: in vivo
human studies.
Study Methodology Treatment Effect Reference
48 healthy individuals Dry rosemary powder2, 5 or 10 g/day, for 8 weeks
↓ FPG
↓ TC, ↓ LDL, ↓ TG, ↑
HDL
↓MDA, ↓ GR
↑ vitamin C
↑ β-carotene
[73]
12 healthy, young volunteers
RE 77.7 mg
↓ PAI-1 [74]COH 0.97 mgCA 8.6 mg
RA 10.30 mg for 21 days
72 patients with rheumatic
disease including osteoarthritis
(OA), rheumatoid arthritis,
fibromyalgia (FM)
Meta050 compound (RE, oleanolic acid
and reduced iso-alpha-acids) ↓ CRP
[75]440 mg/day for 4 weeks 3 times per day ↓ arthritis pain scores
880 mg/day for 4 weeks 2 times per day ↔ fibromyalgia scores
13. Conclusions
Rosemary extract and the rosemary extract polyphenols carnosic acid and rosmarinic acid
have been shown to have insulin-like effects in insulin target cells in vitro and to exert significant
anti-diabetic effects in different animal models of T2DM in vivo. Rosemary extract and rosemary
extract polyphenols exhibit protective properties against hyperlipidemia and hyperglycemia in genetic,
chemically-induced and dietary animal models of obesity and T2DM. These promising findings from
in vivo animal studies suggest a potential to use RE and its polyphenolic constituents towards the
management of blood glucose levels and diabetes. However, more studies are warranted to fill the
gaps in research. On the one end of the research spectrum, in vitro studies are needed to delineate
the direct effects of RE and its polyphenolic constituents in specific cell and tissue types and thereby
ascertain their mechanism of action. On the other end, clinical trials are warranted to examine the
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effects of RE and its polyphenolic constituents directly in humans. Furthermore, more research is
needed to address questions surrounding bioavailability of RE and its polyphenolic components,
and therapeutic dosage ranges relevant in humans.
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Abbreviations
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AST Aspartate transaminase
CA Carnosic acid
CAT Catalase
C/EBPα CCAAT-enhancer binding proteins,
COH Carnosol
CRP C-reactive protein
DDP-4 Dipeptidyl peptide 4
DGAT1 Diacylglycerol acyltransferase 1
ERK Extracellular signal-regulated kinase
FDA Food and Drug Administration
FFA Free fatty acids
FM Fibromyalgia
FPG Fasting plasma glucose
GL Gastric lipase
GLP-1 Glucagon-like peptide 1
GPDH Glycerol-3-phosphate dehydrogenase
GPx Glutathione peroxidase
GSH Glutathione
GU Glucose uptake
HSL Hormone sensitive lipase
HDL High-density lipoprotein
HFD High-fat diet
HbA1c Glycated hemoglobin
IDF International Diabetes Federation
ITT Insulin tolerance test
LDL Low-density-lipoprotein
MCP-1 Monocyte chemoattract protein 1
MDA Malondialdehyde
MUFA Monounsaturated fatty acids
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells
OA Osteoarthritis
OGTT Oral glucose tolerance test
PAI-1 Plasminogen activator inhibitor-1
PEPCK Phosphoenolypyruvate carboxykinase
PL Pancreatic lipase
PPAR Peroxisome proliferator activated receptor,
RA Rosmarinic acid
RE Rosemary extract
ROS Reactive oxygen species
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SCD1 Stearoyl coA desaturase 1
SFA Saturated fatty acids
SGLT1 Sodium glucose cotransporters 1
SGLT2 Sodium-glucose cotransporter 2,
SOD Superoxide dismutase
SREBP1 Sterol regulatory element binding protein 1
STZ Streptozotocin
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TC Total cholesterol
TG Triglycerides
TNFα Tumor necrosis factor α
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